Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

CompletedOBSERVATIONAL
Enrollment

259

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Prostate Cancer
Interventions
DRUG

Depo-Eligard®

Subcutaneous

Trial Locations (23)

1030

Site: 23, Brussels

1090

Site: 13, Brussels

1180

Site: 24, Uccle

1380

Site: 26, Lasne-Chapelle-Saint-Lambert

2018

Site: 5, Antwerp

Site: 8, Antwerp

Site: 9, Antwerp

2020

Site: 14, Antwerp

2170

Site: 33, Merksem

2200

Site: 4, Antwerp

2300

Site: 1, Turnhout

3300

Site: 18, Tienen

3800

Site: 37, Sint-Truiden

4000

Site: 38, Liège

7100

Site: 39, La Louvière

8400

Site: 31, Ostend

8500

Site: 25, Kortijk

8870

Site: 20, Izegem

8900

Site: 21, Ieper

9000

Site: 11, Ghent

9200

Site: 34, Dendermonde

9300

Site: 32, Aalst

9700

Site: 17, Oudenaarde

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Veeda Clinical Research

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT01793077 - Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients | Biotech Hunter | Biotech Hunter